Cipla Limited CIPLA NIFTY50NSEAIPHARMA

Q: What is the current share price of Cipla Limited (CIPLA)?

As of 2026-09-08 04:53 IST, Cipla Limited (CIPLA) trades at ₹1,385.00 on NSE. Its 52-week range is ₹1,181.32 to ₹1,648.14.

Q: What is the market capitalisation of CIPLA?

Cipla Limited (CIPLA) has a market capitalisation of ₹1.12 L Cr on NSE.

Q: What is the P/E ratio of CIPLA?

CIPLA trades at a trailing price-to-earnings (P/E) ratio of 28.85. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 3.43.

Q: Does CIPLA pay a dividend?

Cipla Limited (CIPLA) currently offers a dividend yield of 0.88%.

Q: What is the return on equity (ROE) of CIPLA?

CIPLA has a return on equity (ROE) of 11.27%. Its return on capital employed (ROCE) is 14.86%.

Q: Is CIPLA a good stock to buy?

This page provides a data-driven analysis of Cipla Limited (CIPLA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.cipla.com

Company Profile ↓

₹1,385.00

-8.12% 1Y

Mkt Cap₹1.12 L Cr

P/E28.85

P/B3.43

Div. Yield0.88%

52W High₹1,648.14

52W Low₹1,181.32

Book Value₹426.25

EPS (TTM)₹48.00

Company Overview

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 11.5% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 28.9, below the sector median of 41.6.

Healthy Margins

Operating margin of 17.5% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of ₹27,711.69 Cr (+2.1% YoY); net profit ₹3,879.23 Cr.
Trailing 12 Months Year-on-year growth — revenue +2.1%, earnings -26.4%.
5-Year Trend Long-term compounding — revenue CAGR 7.2%, profit CAGR 11.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	7.23%
1 Year:	2.09%

Compounded Profit Growth

5 Years:	11.45%
1 Year:	-26.43%

Stock Price Performance

1 Year:	-8.12%
6 Months:	+5.81%
3 Months:	+0.62%
1 Month:	-6.23%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

AI Exposure AI Pharma / AI in Operations

Core Focus

Cipla uses AI for inhaler-device optimisation (ARMI), supply-chain AI, and digital therapeutics in respiratory.

Key Initiatives

AI in drug discovery & formulation Cipla applies AI/ML to molecule screening, formulation and generic-development workflows to shorten time-to-market and improve success rates.
AI in manufacturing & quality Machine-learning-driven process control and predictive quality across plants support regulatory compliance and yield.
Digital health & adherence AI-enabled patient-adherence and respiratory-care digital tools extend Cipla's franchise into connected healthcare.

Why Investors Should Care

AI is a productivity lever on R&D and manufacturing for a leading generics/respiratory player.
Solid balance sheet, ROCE ~15.5% and steady ~10% five-year profit CAGR.
Reasonable P/E ~29 for a defensive pharma compounder with optionality in digital health.
AI benefits are incremental rather than transformational — a quality, not hyper-growth, story.

AI InvestmentR&D ~6-7% of revenue; collaborations with US/India AI firms.

AI RevenueRevenue ~₹26,000 Cr.

ROI (Now)EBITDA margin ~25%; ROE ~16%.

ROI (Expected)Respiratory + biosimilars + AI-led mfg expected to drive earnings.

Curated from public filings and analyst commentary; figures are illustrative.

Price Chart

NSE TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Profit CAGR of 11.5% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

28.85

Industry PE

41.64

Forward P/E

21.82

PEG Ratio

Book Value

₹426.25

Price to Book

3.43

P/S

4.21

EV/EBITDA

21.02

Dividend Yield

0.88%

Growth (CAGR)

Revenue 5Y

7.23%

Profit 5Y

11.45%

Revenue (YoY)

2.09%

Earnings (YoY)

-26.43%

Profitability & Returns

ROCE

14.86%

ROE

11.27%

ROA

9.13%

Profit Margin

14.00%

Op Margin

17.49%

Gross Margin

62.28%

EPS (Latest Qtr)

₹9.76

EPS (TTM)

₹48.00

Balance Sheet & Liquidity

Debt/Equity

1.78

Quick Ratio

2.50

Current Ratio

3.44

Debt

₹613.77 Cr

Total Assets

₹42,495.98 Cr

Current Assets

₹24,147.03 Cr

Working Capital

₹17,133.44 Cr

Ownership

Promoter Holding

34.58%

Chg in Prom Hold

3.45%

FII / Inst Holding

44.30%

Chg in FII Hold

-0.16%

Financial Snapshot

Enterprise Value

₹1.12 L Cr

Total Revenue (TTM)

₹27,711.69 Cr

EBITDA

₹6,355.48 Cr

Free Cash Flow

₹860.71 Cr

Operating Cash Flow

₹3,940.02 Cr

Shares Outstanding

₹80.78 Cr

Gross Margin

62.28%

Payout Ratio

31.18%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,385.00	28.85	₹1.12 L Cr	0.88%	14.86%	11.27%	7.23%	11.45%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,899.00	39.73	₹4.56 L Cr	0.82%	17.94%	13.74%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	9,100.00	94.06	₹2.42 L Cr	0.36%	18.96%	15.32%	10.98%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,857.00	75.99	₹1.64 L Cr	0.77%	9.05%	25.79%	13.27%	20.22%
5	APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA	8,650.00	64.10	₹1.24 L Cr	0.22%	19.20%	20.48%	14.85%	33.34%
6	LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA	684.90	236.17	₹1.19 L Cr	0.00%	7.21%	5.65%	35.38%	66.99%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,120.00	22.36	₹1.13 L Cr	0.09%	19.04%	18.59%	16.55%	36.99%
8	LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA	1,840.00	111.85	₹99,333.61 Cr	0.13%	19.53%	16.77%	3.77%	4.00%
9	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,110.00	18.12	₹96,464.79 Cr	0.75%	28.33%	23.76%	19.10%	131.46%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	5,739.00 Cr	6,329.00 Cr	6,678.00 Cr	6,604.00 Cr	6,163.00 Cr	6,694.00 Cr	-	-	6,597.72 Cr	6,837.04 Cr	7,589.00 Cr	6,962.97 Cr	6,464.26 Cr	7,077.02 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	2,189.02 Cr	2,170.71 Cr	-	2,632.08 Cr	2,248.68 Cr	2,667.18 Cr
Gross Profit	-	-	-	-	-	-	-	-	4,408.70 Cr	4,666.33 Cr	-	4,330.89 Cr	4,215.58 Cr	4,409.84 Cr
Operating Expenses	4,566.00 Cr	4,835.00 Cr	4,944.00 Cr	4,856.00 Cr	4,847.00 Cr	4,978.00 Cr	-	-	3,179.84 Cr	3,140.91 Cr	5,695.00 Cr	3,354.18 Cr	3,601.53 Cr	3,521.78 Cr
Operating Income	828.00 Cr	1,255.00 Cr	1,444.00 Cr	1,515.00 Cr	1,028.00 Cr	1,469.00 Cr	-	-	1,228.86 Cr	1,525.42 Cr	1,598.00 Cr	976.71 Cr	614.05 Cr	888.06 Cr
EBITDA	1,174.00 Cr	1,494.00 Cr	1,734.00 Cr	1,748.00 Cr	1,316.00 Cr	1,716.00 Cr	-	-	1,827.05 Cr	2,036.70 Cr	1,895.00 Cr	1,185.49 Cr	1,103.11 Cr	1,403.20 Cr
Interest Expense	34.00 Cr	16.00 Cr	26.00 Cr	30.00 Cr	18.00 Cr	18.00 Cr	-	-	14.02 Cr	14.05 Cr	13.00 Cr	14.03 Cr	13.13 Cr	17.03 Cr
Pretax Income	745.00 Cr	1,375.00 Cr	1,594.00 Cr	1,474.00 Cr	1,259.00 Cr	1,611.00 Cr	-	-	1,504.30 Cr	1,769.93 Cr	1,854.00 Cr	893.11 Cr	707.06 Cr	1,081.93 Cr
Tax Provision	223.50 Cr	385.00 Cr	446.32 Cr	412.72 Cr	327.34 Cr	434.97 Cr	-	-	279.28 Cr	477.88 Cr	500.58 Cr	218.55 Cr	156.95 Cr	294.83 Cr
Net Income	522.00 Cr	998.00 Cr	1,155.00 Cr	1,068.00 Cr	932.00 Cr	1,175.00 Cr	-	-	1,221.84 Cr	1,297.62 Cr	1,353.00 Cr	675.80 Cr	554.64 Cr	789.05 Cr
Diluted EPS	6.51	12.33	14.01	13.08	11.63	14.58	-	-	15.12	16.06	16.73	8.36	6.86	9.76

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	11,345.00 Cr	13,790.00 Cr	14,394.00 Cr	15,156.00 Cr	16,362.00 Cr	17,132.00 Cr	19,160.00 Cr	-	22,473.18 Cr	25,446.63 Cr	27,145.40 Cr	27,711.69 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	8,960.63 Cr	9,592.38 Cr	9,762.74 Cr	10,452.09 Cr
Gross Profit	-	-	-	-	-	-	-	-	13,512.55 Cr	15,854.25 Cr	17,382.66 Cr	17,259.60 Cr
Operating Expenses	9,183.00 Cr	11,310.00 Cr	11,898.00 Cr	12,329.00 Cr	13,265.00 Cr	13,926.00 Cr	14,907.00 Cr	-	9,494.68 Cr	10,485.59 Cr	11,238.44 Cr	12,414.08 Cr
Operating Income	1,658.00 Cr	1,726.00 Cr	1,173.00 Cr	1,503.00 Cr	1,771.00 Cr	2,031.00 Cr	3,184.00 Cr	-	4,017.87 Cr	5,368.66 Cr	6,144.22 Cr	4,845.52 Cr
EBITDA	2,163.00 Cr	2,480.00 Cr	2,496.00 Cr	2,826.00 Cr	3,097.00 Cr	3,206.00 Cr	4,252.00 Cr	-	5,152.10 Cr	6,824.05 Cr	7,860.28 Cr	6,355.48 Cr
Interest Expense	168.00 Cr	207.00 Cr	159.00 Cr	114.00 Cr	168.00 Cr	197.00 Cr	161.00 Cr	-	94.56 Cr	71.13 Cr	44.02 Cr	48.23 Cr
Pretax Income	1,654.00 Cr	1,727.00 Cr	1,222.00 Cr	1,669.00 Cr	2,079.00 Cr	2,178.00 Cr	3,290.00 Cr	-	4,038.35 Cr	5,701.90 Cr	6,820.81 Cr	5,223.63 Cr
Tax Provision	396.96 Cr	328.13 Cr	183.30 Cr	250.35 Cr	561.33 Cr	631.62 Cr	888.30 Cr	-	1,202.86 Cr	1,546.59 Cr	1,529.76 Cr	1,353.84 Cr
Net Income	1,229.00 Cr	1,383.00 Cr	1,035.00 Cr	1,417.00 Cr	1,492.00 Cr	1,500.00 Cr	2,389.00 Cr	-	2,801.91 Cr	4,121.55 Cr	5,272.52 Cr	3,879.23 Cr
Diluted EPS	14.71	16.93	12.51	17.52	18.96	19.18	29.82	31.17	34.69	51.01	65.24	48.00

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	15,670.00 Cr	21,049.00 Cr	20,869.00 Cr	22,673.00 Cr	23,762.00 Cr	23,423.00 Cr	24,855.00 Cr	-	29,463.28 Cr	32,717.82 Cr	37,387.04 Cr	42,495.98 Cr
Current Assets	-	-	-	-	-	-	-	-	17,274.95 Cr	19,441.41 Cr	23,288.52 Cr	24,147.03 Cr
Cash & Equivalents	-	-	-	-	-	-	-	-	627.63 Cr	640.07 Cr	588.69 Cr	1,018.22 Cr
Inventory	-	-	-	-	-	-	-	-	5,156.43 Cr	5,237.95 Cr	5,642.11 Cr	6,596.72 Cr
Receivables	-	-	-	-	-	-	-	-	4,057.00 Cr	4,770.66 Cr	5,506.37 Cr	5,620.05 Cr
Total Liabilities	-	-	-	-	-	-	-	-	5,749.74 Cr	5,915.49 Cr	6,097.79 Cr	7,975.74 Cr
Current Liabilities	-	-	-	-	-	-	-	-	5,109.67 Cr	5,245.77 Cr	5,483.96 Cr	7,013.59 Cr
Long Term Debt	-	-	-	-	-	-	-	-	0	0	11.98 Cr	117.47 Cr
Total Debt	1,703.00 Cr	5,202.00 Cr	4,113.00 Cr	4,098.00 Cr	4,316.00 Cr	2,816.00 Cr	2,014.00 Cr	-	803.12 Cr	559.41 Cr	438.19 Cr	613.77 Cr
Total Equity	10,802.00 Cr	11,517.00 Cr	12,544.00 Cr	14,229.00 Cr	15,012.00 Cr	15,763.00 Cr	18,326.00 Cr	-	23,407.78 Cr	26,706.43 Cr	31,193.45 Cr	34,431.95 Cr
Shares Outstanding	-	-	-	-	-	-	-	-	80.72 Cr	80.74 Cr	80.76 Cr	80.78 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	1,173.00 Cr	1,741.00 Cr	2,382.00 Cr	1,463.00 Cr	1,691.00 Cr	3,068.00 Cr	3,755.00 Cr	-	3,237.65 Cr	4,133.91 Cr	5,004.98 Cr	3,940.02 Cr
Investing Cash Flow	-950.00 Cr	-4,533.00 Cr	-1,304.00 Cr	-834.00 Cr	-1,688.00 Cr	114.00 Cr	-2,374.00 Cr	-	-2,388.51 Cr	-2,988.03 Cr	-3,691.14 Cr	-2,326.13 Cr
Financing Cash Flow	165.00 Cr	3,104.00 Cr	-1,326.00 Cr	-385.00 Cr	-349.00 Cr	-2,949.00 Cr	-1,240.00 Cr	-	-958.29 Cr	-1,200.43 Cr	-1,292.79 Cr	-1,233.65 Cr
Capital Expenditure	-625.00 Cr	-1,053.00 Cr	-1,098.00 Cr	-740.00 Cr	-504.00 Cr	-985.00 Cr	-791.00 Cr	-	-1,182.89 Cr	-1,349.30 Cr	-1,548.20 Cr	-3,079.31 Cr
Free Cash Flow	548.00 Cr	688.00 Cr	1,284.00 Cr	723.00 Cr	1,187.00 Cr	2,083.00 Cr	2,964.00 Cr	-	2,054.76 Cr	2,784.61 Cr	3,456.78 Cr	860.71 Cr
Net Change in Cash	388.00 Cr	312.00 Cr	-248.00 Cr	243.00 Cr	-345.00 Cr	234.00 Cr	141.00 Cr	-	-109.15 Cr	-54.55 Cr	21.05 Cr	380.24 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	60.1%	62.3%	64.0%	62.3%
Operating Margin %	14.6%	12.5%	8.1%	9.9%	10.8%	11.9%	16.6%	-	17.9%	21.1%	22.6%	17.5%
Net Margin %	10.8%	10.0%	7.2%	9.3%	9.1%	8.8%	12.5%	-	12.5%	16.2%	19.4%	14.0%
ROE %	11.4%	12.0%	8.3%	10.0%	9.9%	9.5%	13.0%	-	12.0%	15.4%	16.9%	11.3%
ROCE %	-	-	-	-	-	-	-	-	16.5%	19.5%	19.3%	13.7%

Shareholding Pattern

Insiders

34.58%

Institutions

44.30%

Public Float

67.71%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Vanguard International Stock Index-Emerging Markets Stk	0.89%	72.09 L	₹1,026.21 Cr
2	Vanguard International Stock Index-Total Intl Stock Indx	0.82%	66.30 L	₹943.78 Cr
3	Advisors Inner Circle Fund III-GQG Partners Emerging Markets Equity Fd	0.62%	50.33 L	₹716.43 Cr
4	iShares Core MSCI Emerging Markets ETF	0.54%	43.28 L	₹616.13 Cr
5	Hartford/Schroders Emerging Markets Equity Fd	0.37%	30.16 L	₹429.38 Cr
6	iShares MSCI Emerging Markets ETF	0.24%	19.61 L	₹279.20 Cr
7	DFA Emerging Markets Core Equity Portfolio	0.20%	15.99 L	₹227.59 Cr
8	Fidelity SAI Emerging Markets Low Volatility Index Fund	0.18%	14.31 L	₹203.69 Cr
9	Mercer Emerging Markets Equity Fd	0.15%	11.79 L	₹167.82 Cr
10	Driehaus Emerging Markets Growth Fund	0.14%	11.27 L	₹160.45 Cr

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CIPLA

Google News Fri, 04 Sep 2026

Cipla shares slip after Keytruda biosimilar deal with Qilu, as competition worries weigh; Morgan Stanley... - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxPWG1uTVdOYlRTbEN4RDh3a2k5NWFjWUdzWjd2bVVsbzI1UFVLNlZwUGV4QzlKYWFIcjhkdHUxclk1Ym1xMHg3N0luWkhDeUxickFZUmdISVhuZlhkV2NfcFlUVmRWSkJGZ0xJQ1htdkxPUjdGbXdSN0R3ZkJlN1pMQ0NaQUxDSFlaamJxMk…

Google News Fri, 04 Sep 2026

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field - BusinessLine

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOeDJtQkdKUE5PektvMlcwMU1OeUhWSzFiZlpvWXk5LUQyS2FwcGp3UG1nYlJ2WWJ3VGd1OTNiV0hpZk40dUx6T3BXRGdsaDN4NGhTQkZyemkwUkhzWmxxckt5LVpBWVVqSkNoZkpPQ2o2R0FmQXoxcU1YcmFnTWRxRW1rODVWczdVTnZuMG…

Google News ue, 01 Sep 2026

News by CNBC TV18 on TradingView, 2026-09-01 — cnbctv:d7d1bc073094b:0 - TradingView

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBxdFo4SkNkRzVLX2pybjdKUGdVaXFIdC12ZFVtWmtDUkJ6YWgtYVBlNy1ZQlI5a2w1Mm0zaHNEazFzdGxyZ3lpakItUGFuOVNkUjBReGNHemVZRVNnb3FUaENmdURZUnM?oc=5" target="_blank">News by CNBC TV18 on Trading…

Google News Fri, 04 Sep 2026

Explained: Why Morgan Stanley has the second-lowest price target on the Street for this drugmaker - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPUVlLcHFTZXpZVHp5SF9iZUhUVDJzcHY5SllEMFpoQ0dPOWZmeG1DR1dlSmUxSXBLMWdWbXJUTG0tb3loX3F5N2hleXNDcFg5TmZaV2djRzIyZ1U3MUNfUk9ranpHN3Jod2kwM2ZOejhvTU9tbXdyc3dkRUxyZUFfam5jTGJmM1F5ckhmUE…

Google News Fri, 04 Sep 2026

Stock Alert: IEX, Power Grid, RVNL, Cipla - Business Standard

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOV1BVc1JiRUNxXzhvT2JmZFJ3SExHQ25CSjV0cFZ3UkVNOFJ1YnhwWUxObDBIaGI0OE5XT0dQRGlWMlpCYnNtazcycWprVFFaLWRjeVNscXFQbHVqeDFJQVhoUmJkdjV2aDIwVGFlT1hHS3Y4b1dpekxqbTVZVThWaE12Q0FPQTBBM0xZRk…

Google News ue, 01 Sep 2026

Cipla Shares Gain After Cancer Drug Licensing Deal - equitypandit.com

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPTTM5VGRKMHV2WFpHSEhIYWRWSlF4Zkd3eElXZnI3ZElGUG5FMldUX3lmUExUSXdsUF9NTkc1ZW1LYlZicWE0S0VwNEZ1Vk1Md05Yc1J4enhUUHJNVzNfeXdYV2tHeXFrS1kyVjFYRnVLdDNQN3NRa3pwSU1JMkF0X3dCbmZRSmM?oc=5" …

CIPLA — Frequently Asked Questions

What is the current share price of Cipla Limited (CIPLA)?

As of 2026-09-08 04:53 IST, Cipla Limited (CIPLA) trades at ₹1,385.00 on NSE. Its 52-week range is ₹1,181.32 to ₹1,648.14.

What is the market capitalisation of CIPLA?

Cipla Limited (CIPLA) has a market capitalisation of ₹1.12 L Cr on NSE.

What is the P/E ratio of CIPLA?

CIPLA trades at a trailing price-to-earnings (P/E) ratio of 28.85. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 3.43.

Does CIPLA pay a dividend?

Cipla Limited (CIPLA) currently offers a dividend yield of 0.88%.

What is the return on equity (ROE) of CIPLA?

CIPLA has a return on equity (ROE) of 11.27%. Its return on capital employed (ROCE) is 14.86%.

Is CIPLA a good stock to buy?

This page provides a data-driven analysis of Cipla Limited (CIPLA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks

Cipla Limited CIPLA NIFTY50NSEAIPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Cipla shares slip after Keytruda biosimilar deal with Qilu, as competition worries weigh; Morgan Stanley... - Moneycontrol.com

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field - BusinessLine

News by CNBC TV18 on TradingView, 2026-09-01 — cnbctv:d7d1bc073094b:0 - TradingView

Explained: Why Morgan Stanley has the second-lowest price target on the Street for this drugmaker - CNBC TV18

Stock Alert: IEX, Power Grid, RVNL, Cipla - Business Standard

Cipla Shares Gain After Cancer Drug Licensing Deal - equitypandit.com

CIPLA — Frequently Asked Questions

What is the current share price of Cipla Limited (CIPLA)?

What is the market capitalisation of CIPLA?

What is the P/E ratio of CIPLA?

Does CIPLA pay a dividend?

What is the return on equity (ROE) of CIPLA?

Is CIPLA a good stock to buy?

Explore More